NL-OMON21822招募中不适用
A phase 1 a/1 b/2 study to assess the safety, tolerability and pharmacokinetics of OTL78, a PSMA-targeted fluorescent agent, for the intraoperative imaging of prostate cancer
On Target Laboratories, Inc0 个研究点目标入组 39 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 39
研究概览
简要总结
.A.
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Part A (healthy volunteers)
- •Ten (n=10) healthy volunteers will take part in this study (maximum=15 if a 3rd dosing cohort is added).
- •Inclusion criteria
- •1) Male and 18-65 years old at screening.
- •2) Able and willing to comply with study procedures, with signed and dated informed consent obtained before any study-related procedures are performed.
- •3) Agree to use an effective method of contraception for 90 days after administration.
- •4) A body mass index is =30 kg/m2.
- •5) The subject is healthy with no acute or chronic medical illnesses, has a normal physical examination, and normal vital signs findings at screening.
- •6) The subject’s screening 12-lead ECG and clinical laboratory test results are within normal limits, or if any are outside of normal limits they are considered clinically insignificant at the discretion of the investigator.
- •7) Negative screening test results for hepatitis B, hepatitis C, and human immunodeficiency virus.
- •8) Negative test results for drug and alcohol screening.
- •9) Absence of any psychological, familial, sociological or geographical condition that at the discretion of the investigator could potentially hamper compliance with the study protocol and follow-up schedule, such conditions
- •The study will be performed in maximum 6 patients.
- •Inclusion criteria
- •1) Male patients > 18 years of age and older at screening.
- •2) Able and willing to comply with study procedures, and signed and dated informed consent obtained before any study-related procedures are performed.
- •3) Known or high clinical suspicion of (primary or recurrent) prostate cancer scheduled to undergo a pelvic lymph node dissection for salvage or staging at the LUMC.
- •4) The 12-lead ECG and clinical laboratory test results are within normal limits, or if any are outside of normal limits they are considered clinically insignificant at the discretion of the investigator
- •5) Chronic or acute medical illness that in the discretion of the investigator may confound or complicate the findings in this study
- •6) Patients are clinically fit for surgery
- •7) Agree to use an effective method of contraception for 90 days after administration
- •8) Absence of psychological familial, sociological or geographical condition that at the discretion of the investigator could potentially hamper compliance with the study protocol and follow- up schedule; such conditions should be discussed with the patient during the prescreening period.
- •The study will be performed in maximum 18 patients.
- •Inclusion criteria
- •1) Male patients > 18 years of age and older at screening.
- •2) Able and willing to comply with study procedures, and signed and dated informed consent obtained before any study-related procedures are performed.
- •3) Known or high clinical suspicion of prostate cancer (Gleason score 7+) planned for a prostatectomy at the NKI.
- •4) The 12-lead ECG and clinical laboratory test results are within normal limits, or if any are outside of normal limits they are considered clinically insignificant at the discretion of the investigator
- •5) Chronic or acute medical illness that in the discretion of the investigator may confound or complicate the findings in this study
- •6) Patients are clinically fit for surgery
- •7) Agree to use an effective method of contraception for 90 days after administration
- •8) Absence of psychological familial, sociological or geographical condition that at the discretion of the investigator could potentially hamper compliance with the study protocol and follow- up s
排除标准
- •Healthy volunteers (phase 1 a/1 b)
- •1) Female subjects
- •2) Known acute or chronic disease, abnormal physical examination or blood tests of clinical significance.
- •3) The subject has previously been included in an OTL study.
- •4) Use of prescription drugs within 30 days of screening and during study participation
- •5) Participation in a clinical trial within 90 days of screening or more than 4 times in the previous year.
- •6) History of clinically significant allergies or anaphylactic reactions.
- •7) History of allergy to any of the components of OTL78 or excipients (see Investigator's Brochure).
- •Part B / Part C
- •Patients will be excluded if any of the criteria below apply:
- •1) Any condition that in the opinion of the investigators could potentially jeopardize the health status of the patient
- •2) History of clinically significant allergies or anaphylactic reactions
- •3) History of allergy to any of the components of OTL78 or excipients
- •4) Impaired renal function defined as eGFR<50 ml/min/1.73m2
- •5) Impaired liver function defined as values greater than 3x the upper limit of normal (ULN) for ALT, AST, or 2x the upper limit of normal for total bilirubin (unless due to Gilbert Syndrome)
- •6) Previous participation in an OTL study
研究者
相似试验
进行中（未招募）
1 期
Study for intra-operative imaging of prostate cancer using OTL78Prostate cancerEUCTR2019-002393-31-NLOnTarget Laboratories24
已完成
1 期
Testing safety and efficacy of a live bacterial therapy for the treatment of Helicobacter pylori infectioInfection - Other infectious diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonHelicobacter pylori infectionACTRN12620000923965Servatus Ltd28
招募中
不适用
A phase 1 study with cisplatin and pemetrexed administered before or after stereotactic radiotherapy (SRT) in patients with stage IB non-small-cell lung cancer (NSCLC).non-small-cell lung cancer. longkankerNL-OMON23245prof. dr. EF Smit20
已完成
不适用
A phase 1a/1b/2 study to assess the safety, tolerability and pharmacokinetics of OTL78, a PSMA-targeted fluorescent agent, for the intraoperative imaging of prostate cancerProstate cancerNL-OMON49366OnTarget Laboratories39
进行中（未招募）
1 期
A 2-part study in healthy volunteers to assess the safety and tolerability of the test medicine and explore how it is taken up by the body following single and multiple doses with an optional third part and to compare how the test medicine is taken up by the body when compared to an existing formulation (recipe)Acute Kidney Injury (AKI)Urological and Genital DiseasesISRCTN16476560nicycive Therapeutics Inc.64